The growing prevalence of heart-related issues is driving demand in cardiological care, and in turn, getting interest from private equity firms such as Antin, Arcline and Carlyle; growing regulatory support and biotech company growth are drawing private equity to regenerative medicine; healthcare investors saw wins in the fourth quarter.
The post Last chance to nominate Women in PE; Antin, Arcline, Carlyle pursue heart health appeared first on PE Hub.
Continue Reading
Sign up for FREE to read the full article and access 132K+ alternative investment headlines.